# OnCo record cogent-biosciences (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/cogent-biosciences/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "cogent-biosciences" ;
  schema:name "Cogent Biosciences"@en ;
  schema:description "Cogent Biosciences makes bezuclastinib, a pill that blocks a mutated protein called KIT. It is being tested in a rare gut tumour called GIST and in systemic mastocytosis, a disease of overactive immune cells."@en ;
  schema:url <https://onco.cc/companies/cogent-biosciences/>, <https://www.cogentbio.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.cogentbio.com/>, <https://www.cogentbio.com/pipeline-publications/>, <https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-ex99_1.htm>, <https://www.sec.gov/Archives/edgar/data/1622229/000119312520308501/d72504d8k.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kit/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/fgfr2/> ;
  onco:drugs <https://onco.cc/drugs/bezuclastinib/>, <https://onco.cc/drugs/cgt4859/> ;
  onco:trials <https://onco.cc/trials/nct05186753/>, <https://onco.cc/trials/nct04996875/>, <https://onco.cc/trials/nct06777316/> .